-transparent.png){kind=logo}
We have studied the reproducibility of a bronchial leukotriene (LT) provocation test in asthmatics, and the effect of prior treatment with an oral leukotriene D4/E4 antagonist (SR 2640) on LTD4-induced bronchoconstriction in nine asthmatics in a double-blind placebo-controlled randomized cross-over trial. The reproducibility of the bronchial leukotriene provocation test was high. For a specific patient, the replication variance is 0.2303, and the standard deviation is thus 0.4799, corresponding to 48%, i.e. one halving of the dose or half doubling of the dose. SR 2640 antagonised LTD4 induced bronchoconstriction causing a mean shift of 48% to the right of the dose-response curve as compared with placebo (95% confidence interval being 11-137%). This study demonstrates that bronchial LTD4 provocation test is a safe and reproducible method in asthmatics, and that the method can be used to detect LT-antagonism; furthermore that SR 2640 is a weak LTD4-antagonist in asthmatics.
L Frølund, and
F Madsen, and
J Nielsen
November 1989,
The American review of respiratory disease,
L Frølund, and
F Madsen, and
J Nielsen
August 1991,
The Journal of allergy and clinical immunology,
L Frølund, and
F Madsen, and
J Nielsen
January 1988,
International archives of allergy and applied immunology,
L Frølund, and
F Madsen, and
J Nielsen
May 1987,
The Journal of allergy and clinical immunology,
L Frølund, and
F Madsen, and
J Nielsen
September 1991,
The American review of respiratory disease,
L Frølund, and
F Madsen, and
J Nielsen
March 1999,
The Journal of pediatrics,
L Frølund, and
F Madsen, and
J Nielsen
July 1998,
The European respiratory journal,
L Frølund, and
F Madsen, and
J Nielsen
January 2008,
Pulmonary pharmacology & therapeutics,
L Frølund, and
F Madsen, and
J Nielsen
October 1988,
European journal of pharmacology,
L Frølund, and
F Madsen, and
J Nielsen
September 1995,
International archives of allergy and immunology,
